STOCK TITAN

Lucid Diagnostics (LUCD) 10-K Filings

LUCD NASDAQ

Here are the 10-K annual reports from Lucid Diagnostics Inc. (LUCD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow LUCD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LUCD filings page.

Rhea-AI Summary

Lucid Diagnostics Inc. files its annual report describing a commercial-stage diagnostics business focused on preventing esophageal cancer in at‑risk GERD patients using its EsoGuard DNA test and EsoCheck cell collection device. The company highlights a large estimated U.S. screening market of about $60 billion, backed by ACG, AGA and NCCN guideline references to non‑endoscopic biomarker testing.

Lucid reports net losses of $58.0 million in 2025 and $45.5 million in 2024 and states there is substantial doubt about its ability to continue as a going concern beyond March 2027 without additional capital. It details heavy reliance on equity financings, convertible notes and arrangements with parent PAVmed, which still owns over 27% of the common stock and provides key services.

Recent developments include a $27.0 million equity offering in September 2025, an ATM program for up to $25.0 million of common stock (with $5.3 million sold after year‑end), a U.S. Department of Veterans Affairs contract for EsoGuard at the Medicare payment rate, Highmark Blue Cross Blue Shield coverage in New York, addition to the Russell 2000 and 3000 indexes, and real‑world data on about 12,000 patients supporting technical performance and clinical use.